ALK is the world leader in allergy immunotherapy, providing products as injections, sublingual drops and sublingual tablets. The company offers a digital ecosystem platform connecting allergy sufferers with diagnostic solutions and emergency treatments for anaphylaxis.
Cyborg Score Rationale
Market-leading position in a specialized niche with strong R&D focus and established global presence across 46 countries. Recent regulatory approval for EURneffy needle-free anaphylaxis treatment demonstrates innovation pipeline strength. Strategic foundation ownership and public trading provide stability.
Top Insights
Received positive recommendation for EURneffy 1 mg, a needle-free anaphylaxis treatment for children (January 2026)
Company strategy focuses on sublingual immunotherapy tablets for grass pollen, ragweed, and house dust mite allergies
Present in 46 countries either directly or via partnerships
Invests approximately 20% of revenue annually in research for evidence-based allergy immunotherapy
Named Competitors
Kytopen/Oral Immunotherapy — European allergy immunotherapy competitor
ASIT biotech Platform — Immunotherapy innovation for allergies